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Preparative SDS PAGE as an
Alternative to His-Tag Purification of
Recombinant Amelogenin
Claire M. Gabe, Steven J. Brookes* and Jennifer Kirkham
Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, United Kingdom
Recombinant protein technology provides an invaluable source of proteins for use in
structure-function studies, as immunogens, and in the development of therapeutics.
Recombinant proteins are typically engineered with “tags” that allow the protein
to be purified from crude host cell extracts using affinity based chromatography
techniques. Amelogenin is the principal component of the developing enamel matrix
and a frequent focus for biomineralization researchers. Several groups have reported the
successful production of recombinant amelogenins but the production of recombinant
amelogenin free of any tags, and at single band purity on silver stained SDS PAGE
is technically challenging. This is important, as rigorous structure-function research
frequently demands a high degree of protein purity and fidelity of protein sequence.
Our aim was to generate His-tagged recombinant amelogenin at single band purity
on silver stained SDS PAGE for use in functionality studies after His-tag cleavage. An
acetic acid extraction technique (previously reported to produce recombinant amelogenin
at 95% purity directly from E. coli) followed by repeated rounds of nickel column
affinity chromatography, failed to generate recombinant amelogenin at single band purity.
This was because following an initial round of nickel column affinity chromatography,
subsequent cleavage of the His-tag was not 100% efficient. A second round of nickel
column affinity chromatography, used in attempts to separate the cleaved His-tag
free recombinant from uncleaved His-tagged contaminants, was still unsatisfactory as
cleaved recombinant amelogenin exhibited significant affinity for the nickel column. To
solve this problem, we used preparative SDS PAGE to successfully purify cleaved
recombinant amelogenins to single band purity on silver stained SDSPAGE. The resolving
power of preparative SDS PAGE was such that His-tag based purification of recombinant
amelogenin becomes redundant. We suggest that acetic acid extraction of recombinant
amelogenin and subsequent purification using preparative SDS PAGE provides a simple
route to highly purified His-tag free amelogenin for use in structure-function experiments
and beyond.
Keywords: recombinant amelogenin, His-tag, nickel column chromatography, protein purification, preparative
SDS PAGE
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INTRODUCTION
Amelogenesis involves the incremental secretion of an
extracellular protein matrix by ameloblasts. Amelogenin,
present as a range of related molecules generated through
extracellular proteolysis of several alternatively spliced gene
products, comprises ∼90% of the total extracellular protein
matrix and is essential for normal enamel biomineralisation.
Amelogenin mutations can lead to amelogenesis imperfecta (AI)
in humans (Lagerstrom et al., 1991; Aldred et al., 1992; Lench
and Winter, 1995; Collier et al., 1997; Kindelan et al., 2000; Hart
et al., 2002; Kim et al., 2004; Wright et al., 2009) and mouse
models (Barron et al., 2010) and amelogenin null mice fail to
produce enamel (Gibson et al., 2001; Wright et al., 2009; Smith
et al., 2016). However, the exact function of amelogenin remains
unclear and studies are ongoing to elucidate amelogenin function
and the etiologies that underpin AI when the amelogenin gene is
mutated.
Our own interest is with the effect of a mouse amelogenin
mutation (p.Y64H) on amelogenin aggregation/assembly and
ameloblast secretory trafficking. Wild-type (WT) amelogenin
begins to self-assemble during transit through the ameloblast
secretory pathway (Brookes et al., 2006). On secretion, it forms
“nanospheres” of ∼25–50 nm in diameter in the developing
enamel (Fincham et al., 1995). Ameloblasts are secretory cells that
are adapted to handle the large amount of amelogenin transiting
through the rough endoplasmic reticulum (ER) and Golgi
apparatus (Warshawsky, 1968). This is achieved by utilizing
elements of the unfolded protein response (UPR) (Tsuchiya et al.,
2008) to maintain ameloblast ER proteostasis; as commonly seen
in other secretory cells (Moore and Hollien, 2012). The UPR aids
cells to cope with a large secretory load by increasing ER volume
and protein folding capacity and increasing the cell’s ability
to identify and handle misfolded proteins via ER associated
protein degradation (Travers et al., 2000). This is important,
as up to 30% of proteins destined for secretion can mis-fold
spontaneously (Schubert et al., 2000) leading to pathological
intracellular protein retention and severe ER stress (Ozcan and
Tabas, 2012). Under circumstances when ER stress is abnormally
high and prolonged, the UPR switches from a pro-survival mode
to a pro-apoptotic mode which leads to cell death (Rutkowski
and Kaufman, 2007). Our previous work has shown that
the Amelxp.(Y64H) mutation promotes intracellular amelogenin
retention, stalls the secretory pathway, and triggers the UPR to
switch into pro-apoptotic mode resulting in ameloblast death,
thus classifying this case of AI as a conformational disease
(Brookes et al., 2014). Our current work seeks to investigate
the effect of the p.Y64H mutation on amelogenin-amelogenin
interactions. The availability of highly purified WT and p.Y64H
amelogenin is therefore essential for use in structure-function
studies.
It is possible to purify amelogenin from developing enamel
itself but this requires a ready and plentiful supply of secretory
stage enamel and expertise in protein purification to isolate
a single amelogenin species from the plethora of discrete but
related amelogenin molecules present in the tissue that are
derived by extracellular processing of several alternatively spliced
isoforms (Brookes et al., 1995). This is challenging but the
advantage of purifying native amelogenin from tissue over
producing recombinant protein in E. coli is that the protein will
be phosphorylated at serine 16 via translational modification in
vivo (Takagi et al., 1984; Fincham and Moradian-Oldak, 1993;
Fincham et al., 1994) and this is believed to be important to its
function (Kwak et al., 2009; Wiedemann-Bidlack et al., 2011).
Typically, native enamel proteins are purified from porcine
developing enamel as porcine developing teeth can be obtained
as a by-product of themeat industry (Aoba et al., 1987; Limeback,
1987). Compared to rodent incisors, each porcine tooth provides
a relatively large amount of starting material as the enamel
thickness can be up to ten times that of rodent developing
tissue. However, pigs must be obtained at a specific age to ensure
that developing teeth are in the secretory phase and not all
teeth will be undergoing amelogenesis at the same time. The
main models for studying amelogenesis, the roles of specific
proteins components and any effects of specific mutations are
the mouse and rat. Rodents have the advantage that their incisors
are continually erupting and the required secretory stage enamel
is present in weaned animals of any age. However, the yield
of secretory stage enamel per animal is so small that very few
published studies have used purified rodent amelogenins.
The need to understand AI pathobiology associated with
specific mutations effectively precludes the use of porcine teeth.
In addition, as we reported previously in the case of our p.Y64H
amelogenin mouse model, there are cases where the mutation
results in failure to secrete the affected protein and this in turn
prevents our purifying the protein from the enamel itself. The
challenge of purifying amelogenin fromwhole cell extracts would
be significant and the only viable source of mutated amelogenin
(or for that matter WT rodent amelogenin) is via recombinant
technology.
Recombinant proteins are widely used as therapeutic agents
and as tools to study structure-function relationships, protein
interactions with other molecules and as antigens for antibody
production. E. coli based expression systems are the most widely
used methodology for producing recombinant amelogenin even
though post translational phosphorylation of serine 16 will be
absent. Baculo virus (Taylor et al., 2006; Xu et al., 2006) and
Leishmania (Yadegari et al., 2015) expression systems, having the
potential to carry out post translational phosphorylation have
been used to produce recombinant amelogenin, but as yet do not
appear to have been widely adopted perhaps due to uncertainty
as to whether the amelogenin was phosphorylated. In contrast,
a yeast based expression system has been reported to generate
correctly phosphorylated recombinant amelogenin (Cheng et al.,
2012) but again has not been widely used. Regardless of the
expression system used, the recombinant amelogenin will need
to be purified and freed from host cell proteins, amelogenin
degradation products, and other contaminants arising from the
growth medium. Early reports describing the preparation of
recombinant amelogenin used ammonium sulfate precipitation
followed by repeated rounds of reverse phase chromatography
(Simmer et al., 1994) or ammonium sulfate precipitation
followed by cation exchange chromatography and reverse phase
chromatography (Ryu et al., 1999) to effectively purify the final
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product. However, it is now generally more common to purify
recombinant proteins by engineering the inclusion of either an
N or C-terminal tag comprising of a poly histidine sequence
(“His-tag”) or fused to glutathione S-transferase (GST) (Hochuli
et al., 1988; Smith and Johnson, 1988). His-tags and GST have
a high affinity for immobilized nickel ions and glutathione
respectively which allows the recombinant proteins to be purified
using affinity column chromatography. Tags typically include
a proteolytic cleavage site which allows them to be removed
following elution from the column.
In our hands, both His-tagged WT and p.Y64H amelogenins
are expressed at acceptable levels in E. coli but after nickel column
affinity purification they also invariably contain background
contaminants especially on silver stained SDS PAGE; an issue
also noted by others (Xu et al., 2006). In agreement with Taylor
et al. (2006) we also find that the His-tag cleavage is not 100%
efficient and our final cleaved product is a mixture of tagged
and untagged recombinant proteins. Removal of the His-tag
is desirable for functional studies; especially those focusing on
intermolecular interactions occurring during amelogenesis in the
enamelmatrix. That said, the presence of a His-tag did not greatly
alter the biological activity of recombinant amelogenin on gene
expression in osteoblasts and periodontal ligament fibroblasts
compared to extracts of native amelogenin from developing
enamel (Svensson et al., 2006; Cheng et al., 2012). Certainly, for
our intended applications, the removal of the His-tag is essential
to generate unambiguous data in protein-protein interaction
studies. Typically, contaminating uncleaved His-tagged protein
is removed by a second round of nickel column chromatography.
However, due to the histidine content of amelogenin (including a
tri-histidine motif; Snead et al., 1985), even untagged amelogenin
has a relatively high affinity for nickel, confounding nickel
column separation of His-tagged from non-tagged amelogenins.
The aim of the present work was to develop an adjunctive
purification step to remove background contaminants from
recombinant amelogenins, including uncleaved His-tagged
amelogenin, generating amelogenins with a high degree of purity.
The results of this work lead us to conclude that we can purify
recombinant amelogenin to a high level of purity from E. coli
without the need for a His-tag using a previously reported acetic
acid extraction technique and a single round of preparative
SDS PAGE. This provides a faster means of obtaining purified
recombinant amelogenin free of any residual His-tag remnants
for use in structure-function studies and beyond.
MATERIALS AND METHODS
Expression and Extraction of Recombinant
Amelogenin
Wild-type amelogenin was expressed using a pET28 expression
vector (Novagen, Merck Chemicals Ltd.) modified with a HRV
3C protease site in Rosetta DE3 E. coli cells (Novagen). Once
the cells reached an optical density of 0.6–1.2 recombinant
protein expression was induced by adding isopropyl β-D-
1-thiogalactopyranoside (IPTG). Induction of expression was
confirmed by analytical SDS PAGE. After shaking overnight
incubation at 37◦C, the cells were harvested by centrifugation
and amelogenin-enriched fractions obtained by extraction in
acetic acid as previously reported (Svensson Bonde and Bulow,
2012). In brief, 1 g of pelleted cells were washed by resuspending
in 30 mL of 150 mM NaCl. After centrifugation the pellet
was resuspended in 30 mL 3% acetic acid, sonicated and
heated at 75◦C for 20 min. Insoluble material was pelleted
by centrifugation and the acetic acid extracts were lyophilized.
Lyophilized extracts were dissolved in a minimum volume of
125 mM formic acid and desalted against 125 mM formic acid
using size exclusion chromatography (HiPrep 26/10 column,
GE Healthcare). The volatile formic acid was then removed by
lyophilization.
Affinity Nickel Column Purification of
His-Tagged Recombinant Amelogenins
Extracted Using Acetic Acid
Lyophilized crude extracts of recombinant amelogenin were
dissolved in a minimum volume of nickel column binding
buffer (20 mM imidazole, 4 M urea, 50 mM Tris, 400 mM
NaCl, pH = 7.6), loaded on to a nickel affinity chromatography
column (5 mL HisTrap FF, GE Health Care) up to a maximum
protein load of 40mg and eluted at a flow rate of 4 mL/min.
Unbound proteins (column flow through) were collected.
Bound recombinant amelogenin was eluted by increasing
the imidazole concentration to 200 mM. The recombinant
amelogenin was then buffer exchanged into 125 mM formic
acid using size exclusion chromatography (HiPrep 26/10 column,
GE Healthcare) and the fractions containing recombinant
amelogenin collected and lyophilized. Fractions were analyzed
by analytical SDS PAGE and anti-amelogenin Western blotting
using rabbit IgGs raised against a peptide corresponding to
the amelogenin hydrophilic C-terminal (Brookes et al., 2011)
as described in the Section entitled Analytical SDS PAGE and
Western Blotting.
His-Tag Cleavage
The lyophilized recombinant amelogenin, prepared as described
above, was dissolved at 2 mg/mL in either 50 mM Tris-HCl,
pH = 8 or 0.1 M Na2CO3, pH = 9 (the Na2CO3 buffer system
was trialed in an attempt to improve cleavage efficiency but
also allowed the cleavage products to be directly labeled with
fluorescein at this point if required). The His-tag was removed
enzymatically by adding recombinant restriction grade protease
(HRV3C, Merck) at a concentration of 3 µL enzyme solution per
mg recombinant protein. Cleavage was carried out over 20 h at
4◦C. The resulting cleavage reaction mixture comprising cleaved
recombinant, any uncleaved recombinant, free His-tag and other
contaminants was finally buffer-exchanged into nickel column
binding buffer by size exclusion chromatography ready for a
second round of nickel affinity column chromatography.
Second Round Nickel Column Purification
to Remove Uncleaved Recombinants, Free
His-Tag, and Cleavage Enzyme
A second round of His-tag cleavage was employed to remove
cleaved His-tag and other contaminants present in the cleavage
reaction mixture including any uncleaved recombinant. Cleavage
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products in binding buffer were loaded on to the nickel affinity
column as described in the Section entitled Affinity Nickel
Column Purification of His-Tagged Recombinant Amelogenins
Extracted Using Acetic Acid. Unbound proteins (expected to
contain the cleaved recombinant amelogenin) were collected in
the column flow through. Bound proteins (expected to contain
any uncleaved recombinant amelogenin, His-tag, and His-tagged
HRV3C) were eluted using a stepped imidazole gradient (50, 60,
70, 90, 205, and 400 mM) in order to optimize the separation.
Fractions were analyzed by analytical SDS PAGE as described in
the Section entitled Analytical SDS PAGE and Western Blotting.
Analytical SDS PAGE and Western Blotting
Analytical SDS PAGE was carried out based upon the method
of Laemmli (1970) except 20% v/v glycerol was included in the
resolving gel. Proteins were separated using a 12% resolving
gel at pH 8.8 and a 4% stacking gel at pH 6.8 using Mini-
PROTEAN III or Criterion Cell electrophoresis systems (Bio-Rad
laboratories Ltd., Hertfordshire, UK). Samples were dissolved
in non-reducing SDS PAGE loading buffer (26 mM Tris-HCl
pH 6.8, 10% v/v glycerol, 0.35% w/v SDS, and 0.01% w/v
bromophenol blue). Prior to SDS PAGE samples were heated
at 90◦C for 1.5 min and run at a constant 200 V until the
bromophenol blue reached the bottom of the gel. Loading for
each gel was optimized in each case by running trial gels.
Following electrophoresis, proteins were detected using
Coomassie Blue (Expedeon Ltd., Cambridgeshire, UK) or
silver staining (ThermoFischer Scientific, Leicestershire, UK) or
were transferred to nitrocellulose membranes (Bio-Rad, Ltd.,
Hertfordshire, UK) for Western blot analysis. After blocking and
washing, the membrane was incubated with primary antibody
(rabbit anti-amelogenin teleopeptide; Brookes et al., 2006, diluted
1:2,000 in blocking buffer) for 95min, washed and then incubated
for 90 min with secondary antibody (goat anti-rabbit conjugated
to horse-radish peroxidase diluted 1:3,000 in blocking buffer).
Immunoreactive protein was visualized using DAB with metal
enhancer, (Sigma-Aldrich, Dorsetshire, UK) according to the
manufacturer’s instructions.
Alternative Purification Methodology Using
Preparative SDS PAGE
The cleaved recombinant amelogenin fractions produced by
the second round nickel column purification described above
still contained traces of uncleaved protein and other minor
contaminants when examined using analytical SDS PAGE.
To eliminate this problem both rounds of affinity column
purification were replaced by preparative SDS PAGE. Desalted
and lyophilized cleaved recombinant amelogenin was dissolved
in non-reducing SDS PAGE loading buffer (as described in the
Section entitled Analytical SDS PAGE and Western Blotting)
at a concentration of 5–7mg/1.5mL. Preparative electrophoresis
was carried out using a Model 491 Prep Cell (Bio-Rad Ltd.,
Hertfordshire, UK). A 12% resolving gel was cast in the 28
mm internal diameter gel tube to a height of 9.5 cm with a
2 cm 4% stacking gel. The gel was run at a constant 12 W
power at room temperature using the circulating cooling pump
as recommended by the manufacturer. Once the tracker dye
reached the bottom of the gel, 2.5 mL fractions were collected at
a flow rate of 0.8 mL/min. Fractions of interest were identified
by subjecting every third fraction to analytical SDS PAGE.
All fractions of interest were then subjected to analytical SDS
PAGE to accurately determine any fractions containing cleaved
recombinant amelogenin at single band purity on silver staining.
The methodologies described above are summarized in
Figure 1.
RESULTS
Expression and Extraction of Recombinant
Amelogenin
Total protein was extracted from E. coli both immediately after
the addition of IPTG and 1 h post induction to determine the
presence of any induced recombinant protein expression using
analytical SDS PAGE and Coomassie Blue staining (Figure 2).
One hour after IPTG induction, the results clearly demonstrated
an additional protein band at 27 kDa, corresponding to
the molecular weight of recombinant amelogenin against a
FIGURE 1 | Flow diagrams summarizing the two methodologies described for
purifying His-tagged recombinant amelogenin. (A) Purification of recombinant
His-tagged amelogenin using conventional His-tag column purification.
(B) Alternative methodology described here using preparative SDS PAGE in
place of His-tag column chromatography to purify recombinant His-tagged
amelogenin.
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FIGURE 2 | Coomassie Blue stained analytical SDS PAGE showing IPTG
induction of recombinant amelogenin expression in E. coli. E. coli were
extracted at the time of induction (0) and 1 h post-induction (1 h). IPTG
induced the expression of a 27 kDa protein corresponding to the expected
molecular weight of recombinant amelogenin.
background of multiple components derived from the expression
system.
Acetic Acid Extraction of His-Tagged
Recombinant Amelogenin and Affinity
Nickel Column Purification
We used affinity chromatography to purify His-tagged
recombinant amelogenin following acetic acid extraction of
the crude bacterial extracts (Figure 3). Fractions 1–2 (Figure 3,
Fr1, Fr2) contained the column flow-through i.e., material
that did not bind to the nickel column in 20 mM imidazole
loading buffer. Fractions 3–5 (Figure 3, Fr3–Fr5) contained the
column bound material eluted by 200 mM imidazole, with the
bulk of the material eluting in fraction 3. The fractions were
then characterized by analytical SDS PAGE (Figure 4A) and
Western blotting using anti-amelogenin antibodies (Figure 4B).
Analytical SDS PAGE showed that the original crude bacterial
FIGURE 3 | Nickel column chromatography of the soluble protein extracted
from E. coli using 3% acetic acid. The chromatogram shows fractions
comprising proteins that failed to bind the column in 20 mM imidazole
(flow-through: fractions 1–2) and bound proteins eluted when the imidazole
concentration was increased from 20 to 200 mM (fractions 3–5). The
conductivity trace indicates the increase in imidazole concentration in the
buffer flowing through the column.
acetic acid extract was clearly enriched with the putative
recombinant amelogenin migrating with a relative molecular
weight of∼27 kDa but also contained a number of contaminating
proteins migrating between 10 and 75 kDa. The majority of these
contaminants were not bound by the nickel column and eluted
in the flow through (Figure 4A, fractions 1–2). Fractions 3–5,
eluted from the column in 200 mM imidazole, contained the
putative recombinant amelogenin. The level of contaminants in
the putative recombinant amelogenin fraction was reduced after
nickel affinity chromatography but some contamination was
still evident at this loading. The corresponding anti-amelogenin
Western blot confirmed the identity of the 27 kDa protein to
be recombinant amelogenin. Anti-amelogenin-immunoreactive
protein was also evident at above 27 kDa, as a smear centered on
∼53 kDa. This corresponds to the formation and re-equilibration
of amelogenin complexes (predominantly dimers) that can exist
during SDS PAGE of amelogenin (Limeback and Simic, 1990).
His-Tag Cleavage and Repeated Nickel
Column Purification to Remove Uncleaved
Recombinants, Freed His-Tag, and
Cleavage Enzyme
We attempted to remove the His-tag from recombinant
amelogenin via proteolytic cleavage and then carried out a second
round of affinity chromatography to remove any uncleaved
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FIGURE 4 | SDS PAGE and anti-amelogenin Western blot analysis of the crude 3% acetic acid E. coli extract and nickel column fractions 1–5. (A) Extraction with 3%
acetic acid (Extract) generated an enriched recombinant amelogenin fraction. In particular, bacterial contaminants migrating above 27 kDa were selectively removed
(compare with Figure 2). Fractions 1–2, corresponding to the column flow-through, contained many of the bacterial proteins contaminating the crude acetic acid
extract. Fractions 3–4 contain proteins eluted by 200 mM imidazole. The 27 kDa recombinant protein is further enriched but still contains contaminating proteins.
(B) Corresponding anti-amelogenin Western blot confirms the identity of the 27 kDa recombinant protein as amelogenin. The smear centered on the 53 kDa band
correspond to re-equilibrating amelogenin aggregates stable in SDS (dimers at 53 kDa being the predominant species present).
FIGURE 5 | Coomassie Blue stained SDS PAGE showing His-tag cleavage of recombinant amelogenin and second round of nickel column purification using stepped
elution gradient to optimize purification of cleaved amelogenin from the cleavage reaction mixture. (A) Cleavage of His-tagged 27 kDa recombinant (Uncleaved) with
HRV3C protease was not 100% efficient. The cleaved reaction mixture (Cleaved) contained 24 kDa cleaved and 27 kDa uncleaved recombinant. (B) The cleaved
recombinant was retained on the nickel column despite lacking a His-tag and did not appear in the column flow-through (Flow-through). Subsequent elution with an
increasing stepped imidazole gradient eluted the cleaved recombinant at imidazole concentrations of 50 mM and above but some uncleaved recombinant amelogenin
and lower molecular weight contaminants were co-eluted. The bulk of uncleaved recombinant amelogenin and free His-tags were eluted by 200 mM imidazole.
Elution using 60 mM imidazole was selected since compared to 50 mM this would increase the yield of cleaved recombinant without overly increasing the elution of
uncleaved recombinant as a contaminant.
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amelogenin (still carrying the His-tag), free His-tag and the
cleavage enzyme itself. Following analytical SDS PAGE, it was
clear that that cleavage was only around 50% efficient at
either pH 8 or 9 (Figure 5A and Supplementary Figure 1).
In an attempt to purify cleaved from uncleaved His-tagged
recombinant amelogenin, the sample was applied to the nickel
column in 20 mM imidazole buffer after the cleavage step. Both
cleaved and uncleaved recombinant amelogenins (without and
with the His-tag, respectively) were retained on the column with
very little cleaved recombinant appearing in the column flow
through (Figure 5B). Increasing concentrations of imidazole
buffer were then used in further attempts to optimize separation
of cleaved from uncleaved His-tagged recombinant amelogenin
via a 50–400 mM imidazole stepped gradient. However, low
molecular weight contaminants and a trace of uncleaved
recombinant amelogenin co-eluted with the cleaved recombinant
amelogenin even at the lowest imidazole concentration employed
(Figure 5B). Uncleaved recombinant and free His-tag were
eluted using >200 mM imidazole. The cleavage enzyme, which
is also His-tagged, has a molecular weight of 22 kDa and
theoretically elutes at high imidazole concentration though it was
not present in high enough concentrations to be detected here.
Based on these data, we chose 60 mM imidazole as the optimum
concentration to use for elution in subsequent experiments
(Figure 6) as it would be expected to give a better yield than
50 mM imidazole without eluting appreciably more uncleaved
contaminant.
Alternative Strategy Avoiding a Second
Round of Nickel Column Purification:
Preparative SDS PAGE
Given that a second round of nickel column purification failed
to provide cleaved recombinant amelogenin at single band
purity, we pursued an alternative strategy using preparative SDS
PAGE. Fractions collected from preparative SDS PAGE were
characterized using analytical SDS PAGE and silver staining
(Figure 7). Using this method, cleaved recombinant amelogenin
(without His-tag), migrating at 24 kDa, was completely separated
from the uncleaved recombinant migrating at 27 kDa and any
lower molecular weight contaminants. These were collected in
earlier fractions (data not shown).
DISCUSSION
The production of recombinant proteins is essential to the
study of protein function and particularly in the case of
amelogenins, which are difficult to purify from native tissue
due to their aggregative behavior, multiplicity of isoforms and
their degradation products and scarcity of material in the most
commonly used animal models. In addition, without recourse to
recombinant expression, it would be almost impossible to study
the effects of specific mutations on amelogenin behavior.
Despite much effort to obtain highly purified recombinant
amelogenin using His-tag affinity chromatography we were
unable to produce recombinant amelogenin of single band purity
when analyzed by silver stained SDS PAGE. Apparent single
FIGURE 6 | Silver stained SDS PAGE showing second round of nickel column
purification to separate cleaved and uncleaved recombinant amelogenin. The
bulk of cleaved recombinant amelogenin was eluted by 60 mM imidazole
together with lower molecular weight contaminants and some uncleaved
recombinant. The uncleaved amelogenin was eluted after increasing the
imidazole concentration to 200 mM.
band purity on SDS PAGE can be achieved by reducing sample
load or by employing less sensitive gel staining techniques such
as Coomassie Blue but this merely places any contaminants
below the limit of stain detection. SDS PAGE is a standard
technique for assessing degrees of protein heterogeneity in
sample mixtures but additional analyses such as isoelectric
focusing or mass spectroscopy would be needed to confirm
absolute purity. With that caveat in mind, our goal was to
produce recombinant amelogenin exhibiting single band purity
on silver stained SDS PAGE gels. The challenges were twofold:
(i) removing contaminating bacterial proteins and (ii) separating
contaminating His-tagged recombinant amelogenin from His-
tag-free recombinant amelogenin following His-tag cleavage,
which is <100% efficient.
In an attempt to reduce contamination with bacterial proteins,
we employed a previously described acetic acid extraction
technique that reportedly produces recombinant amelogenin
from E. coli at>95% purity in a single purification step (Svensson
Bonde and Bulow, 2012). This technique is based on the simple
premise that E. coli proteins are insoluble in 3% acetic acid
at 80◦C whereas amelogenin is soluble under these conditions.
In our hands, the technique certainly provided a fraction
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FIGURE 7 | Preparative SDS PAGE purified cleaved recombinant amelogenin to single band purity on silver stained SDS PAGE analytical gels. Fractions 58–79
collected during preparative SDS PAGE of the HRV3C cleavage reaction mixture contained the 24 kDa cleaved and 27 kDa uncleaved recombinant amelogenins.
Enhanced resolution of cleaved recombinant amelogenin was achieved compared with nickel column chromatography shown in Figures 5B, 6.
highly enriched with recombinant amelogenin but this still
contained contaminants easily detectable on silver stained SDS
PAGE. Nevertheless, this initial acetic acid extraction provided
a greatly enriched and “cleaner” sample for subsequent affinity
chromatography on nickel columns. This is important as E. coli
express a number of proteins (e.g., Fur, Crp, ArgE, SlyD, GlmS,
GlgA, ODO1, ODO2, YadF, and YfbG) that are commonly co-
purified when using immobilized metal affinity chromatography
due to their metal chelating properties or clusters of exposed
histidine residues (Bolanos-Garcia and Davies, 2006). Analytical
SDS PAGE followed by silver staining showed that nickel column
chromatography removed some of the residual contaminating
protein from the initial acetic acid extract. Silver staining is
highly sensitive but is non-quantitative so attempts were not
made to quantify the efficiency of this purification step using gel
densitometry.
Our data showed that His-tag cleavage of recombinant
amelogenin by HRV3C protease was far from 100% efficient. This
is in agreement with a previous report using rTEV protease to
remove His-tags from recombinant amelogenin (Taylor et al.,
2006). In some cases, cleavage efficiency was as low as 50% which
significantly impacted on final yield. Poor cleavage efficiency
may be due to steric hindrance blocking access of the enzyme
to the cleavage site (Waugh, 2011). Amelogenin shows a great
propensity to aggregate at physiological pH and temperatures
(Moradian-Oldak et al., 1994, 1995, 1998; Simmer et al., 1994;
Tan et al., 1998; Wiedemann-Bidlack et al., 2007; Aichmayer
et al., 2010) and self assembles via N-terminal and/or C-terminal
interactions to form higher order structures (Paine and Snead,
1997; Moradian-Oldak et al., 2000; Paine et al., 2000, 2003;
Fang et al., 2011; Wald et al., 2017). We therefore hypothesized
that amelogenin-amelogenin interactions may hinder HRV3C
accessing the His-tag cleavage site. However, carrying out
cleavage at 4◦C (data not shown) and increasing the pH to
9.0, (both expected to favor amelogenin monomerization) had
no effect (Supplementary Figure 1). Finally, we increased the
cleavage time to 48 h but again this did not improve cleavage
efficiency (data not shown).
Accepting the fact that His-tag cleavage was not 100% efficient,
we subjected the cleaved sample (containing recombinant
amelogenin with and without His-tags, free His-tag, cleavage
enzyme, and any other residual contaminant) to a second
round of nickel column affinity chromatography. In theory,
the cleaved recombinant amelogenin should have little affinity
for the column after removal of the His-tag ligand and would
be easily collected in the flow through or at low imidazole
concentration while the uncleaved recombinant amelogenin,
free His-tag and HRV3C cleavage enzyme (which is itself His-
tagged) would remain bound to the nickel column. However,
cleaved recombinant amelogenin still exhibited significant
affinity for the nickel column. This may be due to the
high histidine content of amelogenin which includes a tri-
histidine domain (Snead et al., 1985) which can cause non-
specific binding confounding His-tag purification (Schmitt et al.,
1993; Bornhorst and Falke, 2000). The cleaved recombinant
amelogenin could be partially eluted with 50 mM imidazole
but stepwise increases in the imidazole concentration resulted
in the elution of more uncleaved recombinant amelogenin
(Figure 5B). This suggested that several conformational isoforms
of the cleaved recombinant amelogenin were present, each
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FIGURE 8 | Proposed methodology using preparative SDS PAGE purification
of His-tag free recombinant amelogenin.
having a different affinity for the nickel column. The real
problem however was that uncleaved recombinant amelogenin
began to elute as the imidazole concentration approached
60 mM. This meant that eluting the cleaved recombinant
amelogenin with 60 mM imidazole to maximize yield would
result in the co-elution of contaminating uncleaved recombinant
amelogenin. Even elution at 50 mM imidazole resulted in
the co-elution of readily detectable uncleaved recombinant
amelogenin.
To solve this problem we decided to employ preparative SDS
PAGE rather than using nickel column affinity chromatography.
This method was able to separate cleaved recombinant
amelogenin from all contaminants to single band purity on
analytical silver stained SDS PAGE. Substituting nickel column
affinity purification with preparative SDS PAGE reduces the
number of steps and leads to a much purer end product.
Indeed, the excellent resolving power of preparative SDS
PAGE, coupled with the acetic acid extraction technique
makes the need for nickel column purification of His-
tagged recombinant amelogenin redundant. We suggest that
recombinant amelogenin without any His-tag could be purified
to single band purity using preparative SDS PAGE (Figure 8). In
comparison to other more costly and labor intensive methods,
using the acetic acid extraction procedure in combination with
preparative SDS PAGE provides an economical and speedy
method for generating recombinant amelogenin. The lack of an
N-terminal His-tag also eliminates any unwanted amino acids
at the N-terminal remaining after His-tag cleavage. We are
currently re-engineering our recombinant amelogenin vectors to
remove the His-tag to take full advantage of the methodology
described.
The preparative electrophoretic equipment employed here
is not restricted to purifying proteins using SDS PAGE which
separates proteins based on their molecular size. Separations
can also be achieved using native PAGE buffer systems where
proteins, in the absence of SDS, are separated based on their
net charge which in turns depends on pH. The manufacturer’s
instructions provide a range of buffer formulations covering
the pH range 3.8–10.2 which can be further adapted by the
addition of chaotropic agents and uncharged detergents to aid
protein solubility. Although, this additional flexibility is not
required in the application reported here, it may prove useful
if using preparative electrophoresis for other application such
as purifying native enamel proteins extracted from developing
enamel.
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